Eli Lilly and Company
General ticker "LLY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $716.8B (TTM average)
Eli Lilly and Company follows the US Stock Market performance with the rate: 43.3%.
Estimated limits based on current volatility of 1.6%: low 984.90$, high 1016.20$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-02-13, amount 1.73$ (Y0.70%)
- Total employees count: 47000 as of 2024
- US accounted for 19.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Product portfolio replenishment, Regulatory and compliance, Counterfeit products, Government pricing controls
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [759.44$, 1087.57$]
- 2026-12-31 to 2027-12-31 estimated range: [829.70$, 1173.18$]
Financial Metrics affecting the LLY estimates:
- Negative: with PPE of 44.2 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 45.56 > 18.38
- Positive: 19.40 < Shareholder equity ratio, % of 23.59 <= 42.68
- Positive: Interest expense per share per price, % of 0.08 <= 0.73
- Negative: Inventory ratio change, % of 3.00 > 0.80
- Positive: Industry earnings per price (median), % of 6.49 > 4.49
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.50 > 6.11
- Positive: 0.01 < Operating cash flow per share per price, % of 1.75
Short-term LLY quotes
Relationship graph
Long-term LLY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34,124.10MM | $45,042.70MM | $65,179.00MM |
| Operating Expenses | $27,666.20MM | $32,143.70MM | $35,483.00MM |
| Operating Income | $6,457.90MM | $12,899.00MM | $29,696.00MM |
| Non-Operating Income | $96.70MM | $-218.60MM | $-3,966.10MM |
| Interest Expense | $0.00MM | $0.00MM | $795.30MM |
| R&D Expense | $9,313.40MM | $10,990.60MM | $13,337.50MM |
| Income(Loss) | $6,554.60MM | $12,680.40MM | $25,729.90MM |
| Taxes | $1,314.20MM | $2,090.40MM | $5,091.60MM |
| Profit(Loss)* | $5,240.40MM | $10,590.00MM | $20,636.60MM |
| Stockholders Equity | $10,771.90MM | $14,192.10MM | $26,535.00MM |
| Inventory | $5,772.80MM | $7,589.20MM | $13,744.00MM |
| Assets | $64,006.30MM | $78,714.90MM | $112,476.00MM |
| Operating Cash Flow | $4,240.10MM | $8,817.90MM | $16,813.00MM |
| Capital expenditure | $7,392.10MM | $8,403.60MM | $7,841.00MM |
| Investing Cash Flow | $-7,152.70MM | $-9,301.50MM | $-10,972.00MM |
| Financing Cash Flow | $3,495.60MM | $1,230.10MM | $-2,213.00MM |
| Earnings Per Share** | $5.83 | $11.76 | $22.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.